Key result
Statin therapy was associated with a lower incidence of late target lesion revascularization compared to no statin therapy after everolimus-eluting stent implantation.
Why the study?
Clinical evidence evaluating statins for preventing late TLR after newer-generation DES implantation, and differences based on pre-interventional vessel remodeling and vessel size, is limited.
Does statin therapy reduce late target lesion revascularization in patients who underwent everolimus-eluting stent implantation?
Cohort (n=720)
Yes
Does statin therapy reduce late target lesion revascularization in patients who underwent everolimus-eluting stent implantation?
Answers are grounded in this paper and cite their sources.
Statin therapy significantly reduces late target lesion revascularization after everolimus-eluting stent implantation, with greater benefit seen when LDL-C is lowered to <100 mg/dL and in lesions with positive remodeling or non-small vessel size.
Clinical evidence demonstrating the impact of statins for preventing late target lesion revascularization (TLR) after newer-generation drug-eluting stent implantation and differences in the effect of statins on late TLR according to pre-interventional vessel remodeling and vessel size is limited. We retrospectively evaluated 1193 de novo lesions in 720 patients who underwent everolimus-eluting stent implantation using intravascular ultrasound from January 2010 to December 2012. The primary endpoint was late TLR. Lesions were divided into the statin group (n = 825) and non-statin group (n = 368). The incidence of late TLR was significantly lower in the statin than non-statin group (1.7% vs. 5.2%, respectively; p = 0.001), and within the statin group, it was significantly lower in the follow-up low-density lipoprotein cholesterol (LDL-C) < 100 than ≥ 100 mg/dL level subgroup (1.0% vs. 3.6%, respectively; p = 0.006). Furthermore, in positive remodeling lesions and non-small vessel size lesions, the incidence of late TLR was significantly lower in the statin than non-statin group (1.6% vs. 8.5% and 1.3% vs. 5.3%, respectively; p = 0.001 and p = 0.004). Lowering the LDL-C level using statins was more effective for preventing late TLR after everolimus-eluting stent implantation. Evaluating pre-interventional vessel remodeling patterns and vessel size might be helpful to stratify lesions at high risk of late TLR.
No takes yet. Share an insight, caveat, or question.
Asada et al. (2022) conducted a cohort in Coronary artery disease (n=720). Statin therapy vs. No statin therapy was evaluated on Late target lesion revascularization (TLR) (HR 0.25, 95% CI 0.11-0.57, p=0.001). Statin therapy was associated with a lower incidence of late target lesion revascularization compared to no statin therapy after everolimus-eluting stent implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: